



**UNIVERSITI PUTRA MALAYSIA**

***SYNTHESIS AND CHARACTERIZATION OF GADOLINIUM AND  
GOLD-DOPED LAYERED DOUBLE HYDROXIDE AND GRAPHENE  
OXIDE NANOCOMPOSITES FOR THERAPEUTIC AGENT DELIVERY***

**MUHAMMAD SANI USMAN**

**ITMA 2018 16**



**SYNTHESIS AND CHARACTERIZATION OF GADOLINIUM AND  
GOLD-DOPED LAYERED DOUBLE HYDROXIDE AND GRAPHENE  
OXIDE NANOCOMPOSITES FOR THERAPEUTIC AGENT DELIVERY**

By

**MUHAMMAD SANI USMAN**

**Thesis Submitted to School of Graduate Studies, Universiti Putra  
Malaysia, in Fulfilment of the Requirements for the Degree of  
Doctor of Philosophy**

**July 2018**

## COPYRIGHT

All material contained within the thesis, including without limitation text, logos, icons, photographs and all other artwork, is copyright material of Universiti Putra Malaysia unless otherwise stated. Use may be made of any material contained within the thesis for non-commercial purposes from the copyright holder. Commercial use of material may only be made with the express, prior, written permission of Universiti Putra Malaysia.

Copyright © Universiti Putra Malaysia



## DEDICATION

*This thesis is dedicated to my beloved parents Dr. Sani Dawaki Usman  
and Dr. (Mrs) Yalwa Usman*



© COPYRIGHT UPM

Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfillment of the requirement for the degree of Doctor of Philosophy

**SYNTHESIS AND CHARACTERIZATION OF GADOLINIUM AND GOLD-DOPED LAYERED DOUBLE HYDROXIDE AND GRAPHENE OXIDE NANOCOMPOSITES FOR THERAPEUTIC AGENT DELIVERY**

By

**MUHAMMAD SANI USMAN**

**July 2018**

**Chairman: Professor Mohd Zobir bin Hussein, PhD**  
**Faculty: Institute of Advanced Technology**

Multimodal delivery system (MDS) or theranostic delivery system (TDS) is still at its infancy. In this work, the concept of MDS was employed, where magnesium/zinc aluminium-layered double hydroxides (Zn/Mg-Al LDH) and graphene oxide (GO) were used as nanocarriers (host) to intercalate and adsorb therapeutic agents (chlorogenic acid, prochlorotic acid and gallic acid), and contrast agents; gadolinium (Gd) as well as gold nanoparticles (AuNPs) as guest molecules. The Gd contrast agent was used as the main contrast agent for magnetic resonance imaging (MRI) and the AuNPs served as supporting contrast agent.

The therapeutic and contrast agents were used to develop various the LDH and GO-based nanocomposites. The agents were developed based on ion exchange interaction in the LDH and non-covalent  $\pi$ - $\pi$  stacking bonding and OH/COOH hydrogen bonding in the GO. The synthesis routes adopted were the Hummer's modified method for GO and co-precipitation for LDH. The mechanism and physico-chemical properties of the nanocomposite formation were studied via characterization processes, such as transmission electron microscopy (TEM) and field emission scanning electron microscopy (FESEM), which were used for shape, size and morphological studies. Fourier transformed-infrared spectroscopy (FTIR) and Raman spectroscopy were used for chemical interaction studies. Inductive coupled plasma emission spectroscopy (ICP-ES), carbon, hydrogen, nitrogen and sulphur analysis (CHNS) and energy-dispersive X-ray (EDS) were used to study the composition as well as purity of the samples. The crystallinity and phase change was studied with X-ray diffraction (XRD) and the ultra violet – visible spectroscopy (UV-Vis) was used for drug release study. The anticancer

efficacies of the nanocomposites and the pure phases were evaluated using human liver cancer cell lines (HepG2) and mouse fibroblast cell lines (3T3) were used in cytotoxicity studies. The inherent signal optimization was done on a 3 Tesla MRI machine, to determine the diagnostic properties of the nanocomposites.

Subsequent amounts of the loaded therapeutic agents were estimated between 15-60%, depending on the nanocarrier and the therapeutic agent. All the pharmacokinetic releases of the therapeutic agents were best fitted to the pseudo-second order kinetic model. The XRD analysis results confirmed the drug intercalation in the LDH galleries and adsorption on the GO surface. Similarly, the FTIR and Raman spectroscopy confirmed the bonding that occurred between the host and guest molecules. CHNS, ICP-ES and EDX equally showed the presence of all the intended compounds and elements in the nanocomposites. The AuNPs grown on the LDH and GO nanocomposites as observed from TEM and FESEM micrographs were poly-dispersed with various shapes and sizes (2-120 nm).

The nanocomposites were observed to inhibit growth of HepG2 cells and showed less toxic in the 3T3 cell lines. Preliminary MR imaging contrast properties test conducted showed enhanced T1 and T2 signals in the samples containing the nanocomposites.

Based on the highlighted results, TDS could serve as potential replacement for the incumbent toxic anticancer agents, which could be used simultaneously in diagnosis.

Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk Ijazah Doktor Falsafah

**SINTESIS DAN PENCIRIAN KOMPOSIT NANO DWI HIDROKSIDA BERLAPIS DAN GRAPHENE OKSIDA YANG DIDOP GADOLINIUM DAN EMAS UNTUK PENGHANTARAN AGEN TERAPEUTIK**

Oleh

**MUHAMMAD SANI USMAN**

Ogos 2018

**Pengerusi: Professor Mohd Zobir bin Hussein, PhD**  
**Fakulti: Institut Teknologi dan Maju**

Sistem penghantar multimodal (MDS) atau sistem penghantar teranostik (TDS) untuk penghantaran ubat masih di peringkat awal. Konsep sistem penghantar multimodal telah digunakan di dalam projek ini di mana zink/magnesium dwi-hidroksida berlapis (Zn/Mg-Al LDH) dan graphene oksida (GO) telah digunakan sebagai '*nanocarriers*' atau hos. *Nanocarriers* tersebut bertindak sebagai platform untuk interkalasi dan penyerapan agen terapeutik (asid klorogenik, asid prochatetuc dan asid gallic) beserta agen kontras iaitu; gadolinium (Gd) dan partikel nano emas (AuNPs) sebagai molekul tetamu. Agen kontras Gd telah digunakan sebagai agen kontras utama untuk pengimejan resonans magnet (MRI) dan nano partikel emas bertindak sebagai agen kontras sokongan.

Agan-agen terapeutik dan kontras tersebut telah digunakan untuk mensintesis pelbagai nanokomposit dwi-hidroksida berlapis (LDH) dan nanokomposit graphene oksida (GO). Agan-agen tersebut telah disintesis berasaskan interaksi pertukaran ion di dalam LDH, ikatan tidak kovalen  $\pi$ - $\pi$  dan ikatan hydrogen OH/COOH di dalam GO. Kaedah sintesis yang telah digunakan adalah kaedah Hummer diubahsuai untuk GO dan kaedah pemendakan bersama untuk LDH. Mekanisma formasi dan ciri-ciri fiziko-kimia nanokomposit telah dikaji menggunakan pelbagai kaedah pencirian. Mikroskopi transmisi electron (TEM) dan mikroskopi imbasan elektron pemancaran medan (FESEM) digunakan untuk kajian bentuk, saiz dan morfologi.

Spektroskopi transformasi Fourier inframerah (FTIR) dan spektroskopi Raman digunakan untuk kajian interaksi kimia. Spektrometri pancaran plasma gandingan aruhan (ICP-EOS), analisis unsur CHNS dan pengimbas serakan tenaga sinar X (EDX) turut digunakan untuk mengkaji komposisi dan ketulenan sampel. Kristaliniti dan perubahan fasa dikaji menggunakan pembelauan sinar X (XRD), seterusnya spektroskopi ultraungu tampak (UV-VIS) digunakan untuk kajian pelepasan ubat. Kesan anti-kanser nanokomposit dan fasa tulen telah dinilai menggunakan sel kanser hati manusia (HepG2) dan kajian sitotoksiti dijalankan menggunakan sel fibroblast tikus (3T3). Pengoptimuman isyarat yang wujud telah dilakukan menggunakan mesin MRI 3 Tesla untuk menentukan ciri diagnostik nanokomposit yang telah disintesis.

Jumlah agen terapeutik yang telah dimuatkan di dalam hos dianggarkan antara 15 – 60% berdasarkan *nanocarrier* dan agen terapeutik yang digunakan. Pelepasan farmakokinetik untuk semua agen terapeutik adalah didapati mengikut model kinetik tertib pseudo kedua. Keputusan XRD menunjukkan ubat telah diinterkalasi di dalam LDH dan diserap di permukaan GO. Keputusan FTIR dan spektroskopi Raman turut menunjukkan ikatan antara hos dan molekul tetamu. Analisis CHNS, ICP-EOS dan EDX semua menunjukkan kehadiran setiap elemen dan sebatian yang dikehendaki di dalam nanokomposit. AuNPs yang disintesis di atas nanokomposit LDH dan GO telah dianalisis melalui TEM dan FESEM dan didapati terdiri daripada pelbagai bentuk dan saiz (2 – 20nm).

Nanokomposit diperhatikan telah menghalang pertumbuhan sel HepG2 dan adalah didapati kurang toksik terhadap sel 3T3. Ujian awal ciri kontras pengimejan resonans magnet menunjukkan peningkatan isyarat T1 dan T2 di dalam sampel yang mengandungi nanokomposit.

Berdasarkan keputusan yang telah diketengahkan, TDS menggunakan nanokomposit berasaskan Zn/Mg LDH atau GO berpotensi untuk menggantikan agen antikanser toksik yang sedia ada dan pada masa yang sama turut boleh digunakan untuk tujuan diagnosis.



## ACKNOWLEDGEMENT

All praise be to Allah Subhanahu Wa Ta'ala, the most beneficent and the most merciful. My special thanks of gratitude goes to my supervisory committee especially the Chairman, Prof. Dr. Mohd Zobir Hussein, who gave me all the guidance and support I needed during my study period.



I certify that a Thesis Examination Committee has met on 5 July 2018 to conduct the final examination of Muhammad Sani Usman on his thesis entitled "Synthesis and Characterization of Gadolinium and Gold-Doped Layered Double Hydroxide and Graphene Oxide Nanocomposites for Therapeutic Agent Delivery" in accordance with the Universities and University Colleges Act 1971 and the Constitution of the Universiti Putra Malaysia [P.U.(A) 106] 15 March 1998. The Committee recommends that the student be awarded the Doctor of Philosophy.

Members of the Thesis Examination Committee were as follows:

**Tan Yen Ping, PhD**

Senior Lecturer  
Faculty of Science  
Universiti Putra Malaysia  
(Chairman)

**Khamirul Amin b. Matori, PhD**

Associate Professor  
Faculty of Science  
Universiti Putra Malaysia  
(Internal Examiner)

**Nor Azah binti Yusof, PhD**

Professor  
Faculty of Science  
Universiti Putra Malaysia  
(Internal Examiner)

**Sanjib Bhakta, PhD**

Associate Professor  
University of London  
United Kingdom  
(External Examiner)



**RUSLI HAJI ABDULLAH, PhD**

Professor and Deputy Dean  
School of Graduate Studies  
Universiti Putra Malaysia

Date: 27 September 2018

This thesis was submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfillment of the requirement for the degree of Doctor of Philosophy. The members of the Supervisory Committee were as follows:

**Mohd Zobir bin Hussein, PhD**

Professor  
Institute of Advanced Technology  
Universiti Putra Malaysia  
(Chairman)

**Sharida Fakurazi, PhD**

Associate Professor  
Faculty of Medicine and Health Sciences  
Universiti Putra Malaysia  
(Member)

**Mas Jaffri Masarudin, PhD**

Senior Lecturer  
Faculty of Biotechnology and Biomolecular Sciences  
Universiti Putra Malaysia  
(Member)

---

**ROBIAH BINTI YUNUS, PhD**

Professor and Dean  
School of Graduate Studies  
Universiti Putra Malaysia

Date:

## Declaration by graduate student

I hereby confirm that:

- this thesis is my original work;
- quotations, illustrations and citations have been duly referenced;
- this thesis has not been submitted previously or concurrently for any other degree at any other institutions;
- intellectual property from the thesis and copyright of thesis are fully-owned by Universiti Putra Malaysia, as according to the Universiti Putra Malaysia (Research) Rules 2012;
- written permission must be obtained from supervisor and the office of Deputy Vice-Chancellor (Research and Innovation) before thesis is published (in the form of written, printed or in electronic form) including books, journals, modules, proceedings, popular writings, seminar papers, manuscripts, posters, reports, lecture notes, learning modules or any other materials as stated in the Universiti Putra Malaysia (Research) Rules 2012;
- There is no plagiarism or data falsification/fabrication in the thesis, and scholarly integrity is upheld as according to the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) and the Universiti Putra Malaysia (Research) Rules 2012. The thesis has undergone plagiarism detection software.

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Name and Matric No.: Muhammad Sani Usman (GS41068)

## Declaration by Members of Supervisory Committee

This is to confirm that:

- The research conducted and the writing of this thesis was under our supervision;
- Supervision responsibilities as stated in the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) are adhered to.

Signature: \_\_\_\_\_  
Name of  
Chairman of  
Supervisory  
Committee: \_\_\_\_\_

Signature: \_\_\_\_\_  
Name of  
Member of  
Supervisory  
Committee: \_\_\_\_\_

Signature: \_\_\_\_\_  
Name of  
Member of  
Supervisory  
Committee: \_\_\_\_\_

Signature: \_\_\_\_\_  
Name of  
Member of  
Supervisory  
Committee: \_\_\_\_\_

## TABLE OF CONTENTS

	<b>Page</b>
<b>ABSTRACT</b>	i
<b>ABSTRAK</b>	iii
<b>ACKNOWLEDGEMENTS</b>	vi
<b>APPROVAL</b>	vii
<b>DECLARATION</b>	viii
<b>LIST OF TABLES</b>	xvii
<b>LIST OF FIGURES</b>	xix
<b>LIST OF ABBREVIATIONS</b>	xxv
<b>CHAPTER</b>	<b>1</b>
<b>1 INTRODUCTION</b>	<b>1</b>
1.1 Background	1
1.2 Nanomedicine	1
1.3 Nanodelivery Systems	1
1.4 Problem Statement	2
1.5 Hypothesis	3
1.6 Scope of study	3
1.7 Objectives	4
<b>2 LITERATURE REVIEW</b>	<b>5</b>
<b>GADOLINIUM- BASED LAYERED DOUBLE</b>	<b>5</b>
<b>HYDROXIDE AND GRAPHENE OXIDE</b>	
<b>NANO- CARRIERS FOR MAGNETIC RESONANCE</b>	
<b>IMAGING AND DRUG DELIVERY</b>	
2.1 Background	6
2.2 Application of Layered Double Hydroxide in Drug Delivery	7
2.2.1 Drug Delivery System	7
2.3 Application of Graphene Oxide in Drug Delivery	8
2.4 Gadolinium- Based Nanodelivery Systems for MR Imaging and Drug Delivery	8
2.5 Multimodal Theranostic Drug Delivery Systems	9
2.6 Summary	21
2.7 Copyright Permission	22
<b>3 MATERIALS AND METHODS</b>	<b>23</b>
3.1 Materials	23
3.2 Preparations of Nanocomposites	24
3.2.1 Synthesis of Gd-Mg/Zn/Al-Layered Double Hydroxide	24
3.2.2 Synthesis of Graphene Oxide	24
3.2.3 Preparation of Protocatechuic Acid/Gadolinium-Mg/Al LDH	24

3.2.4	Preparation of Protocatechuic Acid/Gadolinium-Mg/Al LDH and AuNPs	25
3.2.5	Preparation of Protocatechuic Acid/Gadolinium-GO	25
3.2.6	Synthesis of Gd-Protocatechuic Acid/Gadolinium-GO and AuNPs	25
3.2.7	Preparation of Chlorogenic Acid/Gadolinium-Zn/Al LDH	26
3.2.8	Preparation of Chlorogenic Acid /Gadolinium-Zn/Al LDH and AuNPs	26
3.2.9	Preparation of Chlorogenic Acid /Gadolinium-GO	27
3.2.10	Preparation of Chlorogenic Acid /Gadolinium-GO and AuNPs	27
3.2.11	Preparation of Gallic Acid/Gadolinium-Zn/Al LDH	27
3.2.12	Preparation of Gallic Acid /Gadolinium-Mg/Al LDH and AuNPs	28
3.2.13	Preparation of Gallic Acid /Gadolinium-GO	28
3.2.14	Preparation of Gallic Acid /Gadolinium-GO and AuNPs	28
3.3	Physico-Chemical Studies and Characterizations	29
3.3.1	Powder X-ray Diffraction	29
3.3.2	Thermal Stability Analysis	29
3.3.3	Transmission Electron Microscopy	29
3.3.4	Field Emission Scanning Electron Microscopy	29
3.3.5	Energy Dispersive X-ray Spectroscopy	30
3.3.6	Ultraviolet–Visible (UV–Vis) Spectroscopy	30
3.3.6.1	Therapeutics Release Study	30
3.3.7	Fourier Transform Infrared Spectroscopy	31
3.3.8	Elemental Analysis	31
3.3.9	Raman Spectroscopy	32
3.3.10	Cell Culture	32
3.3.11	MTT Assay	32
3.3.12	MR Imaging Analysis	33

<b>4</b>	<b>GADOLINIUM-DOPED GALLIC ACID-ZINC/ALUMINIUM-LAYERED DOUBLE HYDROXIDE/GOLD THERANOSTIC NANOPARTICLES FOR A BIMODAL MAGNETIC RESONANCE IMAGING AND DRUG DELIVERY SYSTEM</b>	<b>34</b>
4.1	Introduction	34
4.2	Materials and Methods	36
4.2.1	Materials	36
4.2.2	Synthesis of Gadolinium-Zinc /Aluminium-Layered Double Hydroxide	36
4.2.3	Loading of Gallic Acid into Gadolinium-Zinc /Aluminium-Layered Double Hydroxide	36
4.2.4	Doping of Gold Nanoparticles into Gadolinium-Zinc /Aluminium-Layered Double Hydroxide Nanocomposite	37
4.2.5	Characterization	37
4.2.6	Drug Release Study	38
4.2.7	Cell Culture	38
4.2.8	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Cell Viability Assays	38
4.2.9	Magnetic Resonance Imaging Analysis	39
4.3	Results and discussion	39
4.3.1	X-ray diffraction	40
4.3.2	Drug Release Profile and Kinetics from Nanocomposite	41
4.3.3	Surface Morphology and Elemental Content Analysis	44
4.3.4	Size, Shape and Distribution Analysis	45
4.3.5	Chemical Interaction Studies	48
4.3.6	Thermal Stability Analysis	49
4.3.7	Carbon, Hydrogen, Nitrogen and Sulphur –Inductive Coupled Plasma Analysis	52
4.3.8	In Vitro Cytotoxicity Studies against HepG2 and 3T3 Cell Lines	53
4.3.9	Magnetic Resonance Imaging Studies	54
4.4	Summary	55
4.5	Copyright Permission	56
<b>5</b>	<b>CHLOROGENIC ACID INTERCALATED GADOLINIUM-ZINC/ALUMINIUM LAYERED DOUBLE HYDROXIDE AND GOLD NANOCOMPOSITE FOR MR IMAGING AND DRUG DELIVERY</b>	<b>57</b>
5.1	Introduction	57
5.2	Experimental	60



	5.2.1	Materials	60
	5.2.2	Synthesis of Zinc /Aluminium-Layered Double Hydroxide	60
	5.2.3	Synthesis of Chlorogenic Acid and Gadolinium-Zinc /Aluminium-Layered Double Hydroxide Nanocomposite	61
	5.2.4	Synthesis of Chlorogenic Acid-Gadolinium-Zinc /Aluminium-Layered Double Hydroxide /Gold Nanocomposite	61
	5.2.5	Characterization	61
	5.2.6	In Vitro Drug Release Study and Ultra Violet – Visible Spectroscopy	62
	5.2.7	Cell Culture	62
	5.2.8	MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Cell Viability Assays	63
	5.2.9	Magnetic Resonance Imaging Analysis	63
5.3		Results and discussion	64
	5.3.1	Drug loading analysis	64
	5.3.1.1	Ultra Violet – Visible Spectroscopy	64
	5.3.1.2	Kinetic Fitting of Chlorogenic Acid Release from Gadolinium-Zinc /Aluminium-Layered Double Hydroxide	65
	5.3.2	Transmission Electron Microscopy	69
	5.3.3	X-ray Diffraction Patterns	69
	5.3.4	Thermal Analysis	70
	5.3.5	Chemical Interaction Studies	73
	5.3.6	Morphological Studies	75
	5.3.7	Elemental Composition Analysis	77
	5.3.8	Cytotoxicity Assay of Chlorogenic Acid-Gadolinium-Zinc /Aluminium-Layered Double Hydroxide /Gold Nanocomposite, Chlorogenic Acid and Layered Double Hydroxide against 3T3 and HepG2 Cell Lines.	78
	5.3.9	Magnetic Resonance Imaging Test	79
9	5.4	Summary	80
	5.5	Copyright Permission	81

<b>6</b>	<b>SYNTHESIS AND CHARACTERIZATION OF PROTocatechuic Acid-Loaded Gadolinium- Layered Double Hydroxide and Gold NANOCOMPOSITE FOR THERANOSTIC APPLICATION</b>	<b>82</b>
6.1	Introduction	82
6.2	Materials and Methods	84
6.2.1	Materials	84
6.2.2	Synthesis of Gadolinium –Magnesium g/Aluminium-Layered Double Hydroxide and Intercalation of Protocatechuic Acid	85
6.2.3	Loading of Gold Nanoparticles in Protocatechuic Acid Layered Double Hydroxide-Gadolinium Nanohybrid	85
6.2.4	Characterization	85
6.2.5	Drug Release	86
6.2.6	Cell Culture	86
6.2.7	MTT Cell Viability Assays	87
6.2.8	Magnetic Resonance Imaging Analysis	87
6.3	Results and discussion	88
6.3.1	Spatial Orientation of the Intercalated Protocatechuic Acid in Layered Double Hydroxide Interlayer	88
6.3.2	X-ray Diffraction	88
6.3.3	In Vitro Drug Release Study	89
6.3.3.1	Kinetic Studies of the Drug Release	90
6.3.4	Fourier-Transformed Infrared Spectroscopy	93
6.3.5	Thermal Properties Studies	95
6.3.6	Morphological and Elemental Composition Studies	97
6.3.7	Shape and Particles Size Distribution Studies	98
6.3.8	In Vitro Elemental Composition Studies	98
6.3.9	In Vitro Cytotoxicity and Anticancer Activity Studies	101
6.3.10	Contrast Enhancement	103
6.4	Summary	104
6.5	Copyright Permission	105

<b>7</b>	<b>GRAPHENE OXIDE AS A NANOCARRIER FOR A THERANOSTICS DELIVERY SYSTEM OF PROTOCATECHUIC ACID AND GADOLINIUM/GOLD NANOPARTICLES</b>	<b>107</b>
7.1	Introduction	107
7.2	Materials and Methods	110
7.2.1	Materials	110
7.2.2	Characterization	110
7.2.3	Graphene Oxide Synthesis	110
7.2.4	Synthesis of Graphene Oxide—Gadolinium and Protocatechuic Acid Nanocomposite	111
7.2.5	Synthesis of Gold Nanoparticles on the Graphene Oxide—Gadolinium and Protocatechuic Acid Nanocomposite Surface	111
7.2.6	Drug Loading and Release from Nanocomposite	112
7.2.7	Cytotoxicity Study	112
7.2.7.1	Cell Culture	112
7.2.7.2	Cytotoxicity Evaluation	112
7.2.8	Magnetic Resonance Imaging Analysis	113
7.3	Results and discussion	113
7.3.1	Protocatechuic Acid Release Pattern from Graphene Oxide—Gadolinium and Protocatechuic Acid Nanocomposite	113
7.3.1.1	Protocatechuic Acid Release Kinetics	115
7.3.2	Powder X-ray Diffraction Studies	116
7.3.3	Raman Spectroscopy Studies	117
7.3.4	Thermal Studies	118
7.3.5	Fourier Transformed Infrared Spectroscopy Analysis	121
7.3.6	Transmission Electron Microscopy Studies	123
7.3.7	Cytotoxicity Studies	126
7.3.8	Magnetic Resonance Imaging Studies	128
7.4	Summary	129
7.5	Acceptance Letter	130
<b>8</b>	<b>A BIMODAL THERANOSTIC NANODELIVERY SYSTEM BASED ON [GRAPHENE OXIDE-CHLOROGENIC ACID-GADOLINIUM/GOLD] NANOPARTICLES</b>	<b>131</b>
8.1	Introduction	131
8.2	Materials and Methods	133
8.2.1	Materials	133
8.2.2	Characterization	134
8.2.3	Synthesis of Graphene Oxide	134
8.2.4	Graphene Oxide/Gadolinium and	134

	Chlorogenic Acid Nanocomposite	
8.2.5	Adsorption of Gold Nanoparticles on the Graphene Oxide/Gadolinium and Chlorogenic Acid Nanocomposite	135
8.2.6	Drug Loading and Release Studies	135
8.2.7	Cytotoxicity Study	136
	8.2.7.1 Cell Culture	136
	8.2.7.2 Cytotoxicity Evaluation	136
8.2.8	Imaging Studies	136
8.3	Results and discussion	137
	8.3.1 X-ray Diffraction	138
	8.3.2 Drug Release and Kinetics	139
	8.3.3 Raman Spectroscopy	142
	8.3.4 Chemical Interactions (FTIR) Analysis	143
	8.3.5 Transmission Electron Microscopy	146
	8.3.6 Elemental Composition Studies	148
	8.3.7 Thermal Gravimetric Analysis	150
	8.3.8 Cytotoxicity Studies	152
	8.3.9 Magnetic Resonance Imaging Analysis	153
8.4	Summary	155
8.5	Copyright Permission	155
<b>9</b>	<b>CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE WORK</b>	<b>157</b>
9.1	Conclusions	157
9.2	Comparison Between GO and LDH Nanocarriers in Theranostics	159
9.3	Future Works	160
	<b>REFERENCES</b>	<b>161</b>
	<b>BIODATA OF STUDENT</b>	<b>181</b>
	<b>LIST OF PUBLICATIONS</b>	<b>182</b>

## LIST OF TABLES

<b>Table</b>		<b>Page</b>
2.1.	FDA approved gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI)	11
2.2.	Previous works on gadolinium-based nanoparticles/nanocomposites contrast agents	15
2.3.	Gadolinium based nanocomposites for simultaneous delivery of drug and contrast agents	16
4.1.	Fitted data of correlation coefficients ( $R^2$ ), rate constants ( $k$ ), and half-lives ( $t_{1/2}$ ) of gallic acid released from ZAGGA at pH 7.4 and 4.8.	43
4.2.	FT-IR Functional groups and Absorption bands of LDH, $Gd(NO_3)_3$ , Gallic acid, Gallic acid-Zn/Al-LDH/Gd nanocomposite (ZAGGA), Gallic acid-Zn/Al-LDH/Gd-Au nanocomposite (ZAGGAu)	48
4.3.	Maximum peak temperature ( $T_{max}$ ) decomposition temperature range ( $T_{range}$ ) and change in mass ( $\Delta m$ )	52
4.4.	Elemental analysis results for Zn/Al-layered double hydroxide (LDH) nanocarrier and ZAGGAu nanocomposite.	52
5.1.	Correlation coefficients ( $R^2$ ), rate constants ( $k$ ), and half-life ( $t_{1/2}$ ) of Chlorogenic acid released from ZAGCA at pH 7.4 and 4.8 deduced from their kinetic models	66
5.2.	Thermal properties of the host (LDH), the guest (CA) and the host guest compound together with the absorbed species; ZAGCA and ZAGCAu	73
5.3	FTIR Absorption bands and Functional groups of LDH, $Gd(NO_3)_3$ , Chlorogenic acid, Chlorogenic acid intercalated in LDH-Gd nanocomposite (ZAGCAu), and Chlorogenic acid intercalated in LDH-Gd nanocomposite After AuNPs doping (ZAGCAu)	74
5.4.	Elemental compositions of LDH nanocarrier and Chlorogenic acid LDH/GD-AuNPs (ZAGCAu) nanocomposite	77
6.1.	Correlation coefficients ( $R^2$ ), percentage saturation, rate constant and $t_{(1/2)}$ (min) of protocatechuic acid kinetic release from (MAPGA)	93
6.2.	FTIR Absorption bands and Functional groups of $Gd(NO_3)_3$ , protocatechuic acid, Mg/Al-LDH, PA-intercalated Mg/Al-LDH-Gd	94

nanocomposite (MAGPA), PA-intercalated Mg/Al/Gd LDH coated with AuNPs (MAGPAu).

- 6.3. Elemental composition of the theranostic delivery system (MAGPAu) 101
- 7.1. Correlation coefficients ( $R^2$ ), percentage saturation (%), rate constants ( $k$ ), and half-life ( $t_{1/2}$ ) of protocatechuic acid release at pH 7.4 and 4.8 PBS from GOGPA as derived from the models. 118
- 7.2. Decomposition temperature range (Trange) maximum peak temperature (Tmax) and change in mass (Delta m). 119
- 7.3. FTIR Absorption bands and Functional groups GO, protocatechuic acid,  $Gd(NO_3)_3$  protocatechuic acid loaded on GO/Gd nanolayers and gold nanoparticles coated on GOGPA nanocomposite (GOGPAu). 122
- 8.1. Kinetic models information deduced from correlation coefficients ( $R^2$ ), percentage saturation (%), half-life ( $t_{1/2}$ ) and rate constants ( $k$ ) of chlorogenic acid from GOGCA at pH 7.4 and 4.8. 141
- 8.2. FTIR Absorption bands and Functional groups of GO, chlorogenic acid,  $Gd(NO_3)_3$ , GO/Gd conjugated with chlorogenic and the bimodal delivery system [(GOGCAu (BIT) GOGCA coated with AuNPs]. 146
- 8.3. Elemental compositions (%) of GO nanosheet and the BIT (GOGCAu) 150
- 8.4. Elemental composition of GO GOGCAu nanohybrid 149
- 8.5. Decomposition temperature range (Trange) maximum peak temperature (Tmax) and changes in mass (Delta m) 152

## LIST OF FIGURES

Figure		Page
2.1	Schematic representation of <i>host-guest</i> interactions between nanomaterials as carrier serving as host and other molecules as guests (a). Theranostics delivery agent can be obtained by simultaneously loading both the therapeutic and diagnostic agents on the same nanomaterial. On the other hand, multimodal theranostics delivery agent is obtained if all the three agents or more are loaded on a nanomaterial, simultaneously (b).	14
2.2	Schematic representation of Gd intercalated within LDH layers.	17
2.3	Schematic representation of Gd incorporated onto GO layers.	19
4.1	Schematic arrangement of ZAGGAu nanocomposite in respect to theranostic delivery system in a typical <i>host-guest</i> relationship	40
4.2	(a) X-ray diffractograms of (A) $Gd(NO_3)_3$ , (B) Zn/Al-LDH, (C) pure gallic acid, (D) gallic acid-Zn/Al-LDH-Gd nanocomposite (ZAGGA), (E) gallic acid-Zn/Al-LDH/Gd-Au nanocomposite (ZAGGAu); (b) Release profiles of gallic acid intercalated into Zn/Al-LDH-Gd nanoparticles (ZAGGA) in phosphate-buffered solutions at pH 4.8 and pH 7.4; (c) Data of gallic acid released from ZAGGA obtained at pH 4.8 fitted to pseudo-second order; (d) Data of gallic acid released from ZAGGA obtained at 7.4 fitted to pseudo-second order.	43
4.3	(a) Field emission scanning electron microscopy (FESEM) micrograph (A) and (b) Energy dispersive X-ray (EDX) spectrum (1) of gallic acid intercalated in LDH/Gd nanoparticles coated with AuNPs (ZAGGAu); (c) micrograph (B); and (d) EDX spectrum (2) of gallic acid intercalated in LDH/Gd nanoparticles (ZAGGA).	45
4.4	(a) Transmission electron microscopy (TEM) micrograph (A) and particle size distribution of gallic acid-intercalated in Zn/Al-LDH/Gd nanoparticles coated with AuNPs (ZAGGAu) and micrograph (B); (b) of gallic acid intercalated in Zn/Al-LDH/Gd nanoparticles (ZAGGA).	47

4.5	Fourier transform infrared spectroscopy (FT-IR) spectra (A) LDH, (B) $Gd(NO_3)_3$ , (C) pure gallic acid, (D) gallic acid-Zn/Al-LDH/Gd nanoparticles (ZAGGA), (E) Gallic acid-Zn/Al-LDH/Gd-Au nanoparticles (ZAGGAu).	49
4.6	(a) Thermogravimetric and differential thermogravimetric analyses (TGA/DTG) thermograms of pure LDH; (b) pure gallic acid; (c) gallic acid-LDH/Gd nanoparticles (ZAGGA); (d) gallic acid-LDH/Gd-Au nanoparticles (ZAGGAu).	51
4.7	Cytotoxicity study of ZAGGAu, LDH, and free drug at various concentrations exposed to (a) cancer cell lines (HepG2) and; (b) normal cell lines (3T3).	54
4.8	ZAGGAu image at different $Gd^{3+}$ concentrations (2.0, 0.5, 0.2 w/v), $Gd$ (0.5) w/v and water taken from magnetic resonance imaging MRI Prisma 3-Tesla machine.	55
5.1	Multimodal theranostic delivery agent with therapeutic, diagnostic, targeting and other agents in a host/guest interaction.	59
5.2	Drug release profiles of Chlorogenic acid from Chlorogenic acid intercalated LDH-Gd (ZAGCA) nanocomposite.	65
5.3	Data of Chlorogenic acid release from LDH-Gd (ZAGCA) nanohybrid obtained at pH 7.4 and 4.8 fitted to pseudo-second order.	66
5.4	HRTEM micrographs of: A) Chlorogenic acid intercalated LDH-Gd nanocomposite coated with AuNPs (ZAGCAu) and size distribution of the AuNPs, B) Chlorogenic acid intercalated LDH-Gd nanocomposite (ZAGCA).	68
5.5	X-ray diffractograms of: A $Gd(NO_3)_3$ , B (Chlorogenic acid pure), C (LDH), D (Chlorogenic acid intercalated LDH-Gd nanocomposite, ZAGCA), and E (Chlorogenic acid intercalated LDH-Gd nanocomposite coating with AuNPs ZAGCAu).	69
5.6	JCPDS reference file for the AuNPs.	70
5.7	TGA/DTG thermograms of pure LDH (A), pristine Chlorogenic acid (B), Chlorogenic acid intercalated LDH-Gd nanocomposite, ZAGCA (C) and Chlorogenic acid intercalated LDH-Gd nanocomposite coated with AuNPs, ZAGCAu (D).	72
5.8	FTIR spectra of: A (LDH), B (pure $Gd(NO_3)_3$ ), C (CA pure), D Chlorogenic acid intercalated in LDH-Gd nanocomposite	75



(ZAGCA), and E Chlorogenic acid intercalated in LDH-Gd nanocomposite After AuNPs doping (ZAGCAu).

- 5.9 FESEM micrographs and EDS spectra of: A, ZAGCA nanocomposite and B, Chlorogenic acid LDH/GD-AuNPs (ZAGCAu). 77
- 5.10 Cell viability data of cancer cell lines (HepG2) and human cell lines (3T3) exposed to different concentrations of Chlorogenic acid LDH/GD-AuNPs (ZAGCAu), free chlorogenic acid and LDH. 79
- 5.10 Image of Chlorogenic acid LDH/GD-AuNPs (ZAGCAu) at different  $Gd^{3+}$  concentration (2.0, 0.5 and 0.2 w/v), Gd (0.5) w/v and water taken from MRI Prisma 3-Tesla machine. 80
- 6.1 The 3-dimensional spatial orientation of protocatechuic acid and molecular structural model of protocatechuic acid and Gd intercalated between Mg/Al-layered double hydroxide as well as AuNPs adsorbed on the surface. 89
- 6.2 X-ray diffractograms of (A) pure protocatechuic acid, (B)  $Gd(NO_3)_3$  (C) Mg/Al-LDH, (D) drug-intercalated Mg/Al-LDH-Gd nanocomposite (MAPGA) (E), drug-intercalated Mg/Al-LDH-Gd coated with AuNPs (MAPGAu). 91
- 6.3 Protocatechuic acid release profiles from Mg/Al-LDH-Gd nanocomposite in PBS media at pH 4.8 and 7.4. 91
- 6.4 Protocatechuic acid kinetic fitting of release data from Mg/Al-LDH-Gd nanocomposite in PBS media at pH 4.8 and 7.4. 92
- 6.5 FTIR spectra of (A) pure  $Gd(NO_3)_3$  (B) pure protocatechuic acid, (C) Mg/Al-LDH, (D) drug-intercalated Mg/Al-LDH-Gd nanocomposite (MAPGA), (E) drug-intercalated Mg/Al-LDH-Gd coated with AuNPs (MAPGAu). 95
- 6.6 TGA thermograms of (A) Mg/Al-LDH, (B) pure protocatechuic acid, (C) drug intercalated Mg/Al-LDH-Gd nanocomposite (MAPGA), (D) drug intercalated Mg/Al-LDH-Gd coated with AuNPs (MAPGAu). 97
- 6.7 FESEM micrographs of (a) drug-intercalated Mg/Al-LDH-Gd coated with AuNPs (MAPGAu), (b) drug-intercalated Mg/Al-LDH-Gd nanocomposite (MAPGA) and EDS spectra of (i) drug-intercalated Mg/Al-LDH-Gd coated with AuNPs (MAPGAu), (ii) drug-intercalated Mg/Al-LDH-Gd nanocomposite (MAPGA). 99

6.8	TEM micrographs of (a) drug-intercalated Mg/Al-LDH-Gd coated with AuNPs (MAPGAu) and (b) drug-intercalated Mg/Al-LDH-Gd nanocomposite (MAPGA).	100
6.9	Cell viability results of LDH-Gd with protocatechuic acid and AuNPs (MAPGAu), pure protocatechuic acid and the LDH nanocarrier tested with cancer cell lines (HepG2) and normal fibroblast cell lines (3T3)	102
6.10	T1-weighted image of the protocatechuic acid-loaded LDH/Gd-AuNPs nanocomposite (MAPGAu) taken from MRI Prisma 3-Tesla machine at varied concentrations of $Gd^{3+}$ (2.0, 0.5 and 0.2 w/v), Gd (0.5) w/v and water.	104
7.1	(a) Active agents-loaded of GOGPAu nanocomposite in a theranostic nanodelivery system. Diagnostic agents, gadolinium (green) and AuNPs (yellow) and the anticancer agent, PA are attached on a graphene oxide sheet via hydrogen bond, $\pi$ - $\pi$ interaction and electrostatic interaction (GOGPAu); (b) Release profiles of protocatechuic acid from GO-Gd/PA nanocomposite (GOGPA) in pH 7.4 and 4.8 media; (c) Pseudo-second order kinetic plot of protocatechuic acid release data at pH 4.8 medium from GOGPA nanocomposite (Drug-GO/Gd); (d) Pseudo-second order kinetic plot of protocatechuic acid release data at pH 7.4 medium from GOGPA nanocomposite (Drug-GO/Gd).	114
7.2	(a) PXRD diffractograms of the pure protocatechuic acid, GO nanosheets, protocatechuic acid loaded on GO/Gd nanolayers (GOGPA) and gold nanoparticles coated on GOGPA nanocomposite (GOGPAu); (b) Raman spectra of GO nanosheets (A), protocatechuic acid loaded on GO/Gd nanolayers (GOGPA) (B) and gold nanoparticles coated on GOGPA nanocomposite (GOGPAu) (C).	117
7.3	TGA (Blue) and DTG (Red) thermograms of (a) GO nanosheets; (b) pure protocatechuic acid; (c) protocatechuic acid loaded on GO/Gd nanolayers (GOGPA); (d) gold nanoparticles coated on GOGPA nanocomposite (GOGPAu).	120
7.4	FTIR spectra of GO nanosheets (A); pure protocatechuic acid (B); pure $Gd(NO_3)_3$ (C) protocatechuic acid loaded on GO/Gd nanolayers (GOGPA) (D); and gold nanoparticles coated on GOGPA nanocomposite (GOGPAu) (E).	123
7.5	(a) TEM micrographs of protocatechuic acid loaded on GO/Gd nanocarrier (GOGPA) at high and low magnifications; (b) TEM micrographs of protocatechuic acid loaded on GO/Gd nanocarrier after surface coating with gold nanoparticles (GOGPAu).	125

7.6	(a) Cytotoxicity results of pure GO nanosheets, pure protocatechuic acid and protocatechuic acid loaded on GO/Gd nanocarrier after surface coating with gold nanoparticles (GOGPAu) dosed in normal fibroblast cell lines (3T3); (b) cytotoxicity results of pure GO nanosheet, pure protocatechuic acid and protocatechuic acid loaded on GO/Gd nanocarrier after surface coating with gold nanoparticles (GOGPAu) dosed in cancer cell lines (HepG2).	127
7.7	T1-weighted image of protocatechuic acid loaded on GO/Gd nanocarrier after surface coating with gold nanoparticles (GOGPAu) acquired using Prisma 3-Tesla MRI at 2.0, 0.5 and 0.2 w/v concentrations of Gd <sup>3+</sup> , 0.5 (Gd w/v) and water reference.	129
8.1	A bimodal theranostic nanodelivery system (BIT) composition, as in GOGPAu nanocomposite; Diagnostic agents, gadolinium (green) and AuNPs (yellow) and the conjugated anticancer agent, PA (blue) are attached on a graphene oxide sheet via hydrogen bond and interaction.	137
8.2	X-Ray diffraction patterns of pure chlorogenic acid (A), GO nanosheet (B), GO/Gd conjugated with chlorogenic acid (GOGCA) (C) and the bimodal delivery system [GOGCAu (BIT)] composed of GOGCA-coated with AuNPs (D).	139
8.3	Chlorogenic acid release profiles from GOGCA nanocomposite in PBS media at pH 7.4 and 4.8.	141
8.4	The data of chlorogenic acid release from the nanocomposite at pH 7.4 and 4.8 media as fitted to pseudo-second order kinetic model.	142
8.5	Raman spectra of GO nanosheets (A), GO/Gd conjugated with chlorogenic acid (GOGCA) (B) and the bimodal delivery system [GOGCAu (BIT)] (BIT) GOGCA coated with AuNPs] (C).	143
8.6	FTIR spectra of GO nanosheets (A), pure chlorogenic acid (B), Gd(NO <sub>3</sub> ) <sub>3</sub> (C) GO/Gd conjugated with chlorogenic acid (GOGCA) (D) and the bimodal delivery system [GOGCAu (BIT)] GOGCA coated with AuNPs] (E).	145
8.7	TEM micrographs of GO nanocarrier conjugated with chlorogenic acid and Gd (GOGCA) at different magnifications.	147

8.8	TEM micrographs of GO nanocarrier conjugated with chlorogenic acid and Gd (GOGCA) after coating with AuNPs [GOGCAu (BIT)].	148
8.9	Energy dispersive X-ray spectroscopy scale, mapping and spectrum of GO conjugated with chlorogenic acid and Gd, as well as coated with AuNPs [GOGCAu (BIT)].	149
8.10	TGA thermograms of GO nanosheets (A), pure chlorogenic acid (B), GO/Gd conjugated with chlorogenic acid (GOGCA) (C) and the bimodal delivery system [GOGCAu (BIT)] GOGCA coated with AuNPs] (D).	151
8.11	Cytotoxicity results of fibroblast cell lines (3T3) cell lines dosed with pure GO nanosheets, pure chlorogenic acid and GO/Gd nanocarrier loaded with chlorogenic acid and coated with gold nanoparticles [GOGCAu (BIT)] dosed in normal (B) Cytotoxicity results of human liver hepatocellular carcinoma cell lines (HepG2) dosed with pure GO nanosheets, pure chlorogenic acid and GO/Gd nanocarrier loaded with chlorogenic acid and coated with gold nanoparticles [GOGCAu (BIT)].	153
8.12	T1-weighted image of GO/Gd nanocarrier loaded with chlorogenic acid and coated with gold nanoparticles (BIT) at different Gd <sup>3+</sup> concentrations (2.0, 0.5 and 0.2 w/v), 0.5 (Gd w/v) attained from a Prisma 3-Tesla MRI and water reference.	154

## LIST OF ABBREVIATIONS

AgNPs	Silver nanoparticles
AuNPs	Gold nanoparticles
CuNPs	Copper nanoparticles
CA	Chlorogenic acid
LHs	Layered hydroxides
LDH	Layered double hydroxides
GO	Graphene oxide
DNA	Deoxyribonucleic acid
MRI	Magnetic Resonance Imaging
UV	Ultraviolet -Visible
LHs	Layered hydroxide salt
WHO	World Health Organization
DOX	Doxorubicin
MTX	Methotrexate
5-Flu	5-Fluorouracil
CPT	Camptothecin
PCA/PA	Protocatechuic
GA	Gallic acid
FRA	Ferulic acid
DFUR	Doxifluridine
CET	Cetirizine
HA	Hippuric acid
CFX	Ciprofloxacin
CA	Chlorogenic acid
ET	Etopoxide
PPT	Podophyllotoxin
TEM	Transmission electron microscopy
PET	Positron emission tomography
CT	Computed tomography
Gd	Gadolinium
FA	Folic acid
T1	Spin-lattice relaxation
T2	Spin-spin relaxation
Gd-DTPA	Gadopentetate dimeglumine
DTPA	Diethylenetriaminepentaacetic acid
PET-CT	Positron emission tomography-computed tomography
PEG	Polyethylene glycol
3T3	Normal fibroblast cell lines
Hela	Cervical cell lines
HepG2	Human liver hepatocellular carcinoma cell lines
MDA-MB-231	Breast cancer cell lines

T	Tesla
NGO	Nanographene oxide
DMSO	Dimethyl sulfoxide
DEMEN	Dulbecco's Modified Eagle Medium
MTT	(3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide)
PBS	Phosphate-buffered saline
KMnO <sub>4</sub>	Potassium Permanganate
H <sub>3</sub> PO <sub>4</sub>	Ortho-phosphoric acid
HCl	Hydrochloric acid
MAPGA	Protocatechuic Acid/Gadolinium-Mg/Al LDH
MAPGAu	Protocatechuic Acid/Gadolinium-Mg/Al LDH/AuNPs
GOGPA	Graphene oxide-gadolinium and protocatechuic acid nanocomposite
GOGPAu	Graphene oxide-gadolinium and protocatechuic acid nanocomposite/AuNPs
ZAGCA	Chlorogenic acid/gadolinium-Zn/Al LDH nanocomposite
ZAGCAu	Chlorogenic acid/gadolinium-Zn/Al LDH nanocomposite/AuNPs
GOGCA	Chlorogenic Acid /Gadolinium-Graphene oxide
GOGCAu	Chlorogenic Acid /Gadolinium-Graphene oxide/AuNPs
GOGGA	Gallic Acid/Gadolinium-Zn/Al LDH
GOGGAu	Gallic Acid/Gadolinium-Zn/Al LDH/AuNPs
EDS	Energy dispersive X-ray spectroscopy
FTIR	Fourier-transform infrared
ICP-ES	Inductively coupled plasma atomic emission spectrometry
CHNS	Carbon, Hydrogen, Nitrogen, and Sulphur Analysis
MDS	Multimodal delivery systems
XRD	X-ray diffraction
TGA/DTG	Thermogravimetric and Differential thermogravimetric analyses
SPC	Supramolecular chemistry
GOGPAU	Graphene oxide-based theranostic nanodelivery system
TDS	Theranostic delivery systems
BIT	Bimodal theranostic nanodelivery system
FBV	Fetal bovine serum

# CHAPTER 1

## INTRODUCTION

### 1.1 Background

The concept of “nanotechnology” was first introduced by an American physicist known as Richard Feynman as far back as 1959 [1, 2]. The concept of Nanotechnology is still being utilized in various fields of science and other areas of researches, such as nanomedicine, despite age of its inception. As a matter of fact, new research areas such as theranostics, that are currently emerging are based on nanotechnology theory. Nanotechnology is a simple term in any area of science or technology that involves the use of materials within the nanoscale dimensions (nanomaterials).

Nanomaterials are generally considered materials with at least a dimension within the nanoscale. The generally accepted nanoscale is 1-100 nm [3].

### 1.2 Nanomedicine

Nanomedicine is considered as any field or area of nanotechnology that is applied to prevent or treat human diseases. "Nanomedicine" was first reported by Drexler et al., 1991 [4]. Nanomedicine is vast and covers a wide range of research areas, from materials to engineering, so long the materials used are within the nanoscale [5]. One of the most promising areas of nanomedicine is in novel therapeutics and drug delivery systems, which has reached the level of clinical in some areas of the advanced world [6-8]. Nevertheless, the use nanotechnology in multifunctional delivery for targeting of specific diseases or multiple diseases across biological barriers is still at its infancy stage. Consequently, there is yet to be an established framework for administering dose for nanomaterials-based drug [9].

### 1.3 Nanodelivery Systems

Nanodelivery system refers the use of nanomaterials or nanostructured as delivery agents for materials, mainly therapeutic agents, diagnostic or the combination of both (theranostic), and other food bioactives [10]. The system offers an opportunity for stability, solubility improvement and control, bioavailability as well as reduction in toxicities of therapeutic agents [11, 12].

*Multimodal or multifunctional nanodelivery systems* are very much at early stage. The system encompasses therapeutic and diagnostic agents with more than one imaging applications [13]. As mentioned earlier, the most important aspect of nanoscience in nanomedicine is the area of drug delivery; the purpose of drug targeting is to enable site-specific delivery of the drugs, which would help in doing away with unwanted side-effects. The nanocarrier can easily be used in drug dosage control since the drugs will be delivered to a specific target. Lately, nanotechnology is being applied in the simultaneous diagnosis and treatment of cancer related diseases in theranostic delivery systems [14]. The system is derived from the wide knowledge of molecular science of human body. The therapeutic agents used in this work are listed below:

*Gallic acid (GA)* is naturally occurring polyhydroxyl phenolic compound that can be found in different varieties of fruits. It has medicinal and disease preventive properties, such as anti-inflammatory, antibacterial and antiviral. The natural product has anticancer properties, which makes it good candidate for cancer chemotherapy. [15, 16]. However, the anticancer properties of the plant-based material is yet to be fully explored.

*Protocatechuic acid (PA)* is a natural product of numerous medicinal plants sources. The plants include *hibiscus sabdariffa* L, *hypericum perforatum* L and *Ginkgo biloba* L, whereas the pharmacological properties of the protocatechuic acid include, anti- antimicrobial [17], inflammatory [18], cardioprotective and antigenotoxic [19], antimutagenic [20], and most importantly anticancer [21] and antitumor [22]. The therapeutic agent has potentials of being a worthy anticancer agent.

*Chlorogenic acid (CA)* is a phenolic compound that is naturally occurring and originates from coffee. Chlorogenic acid has medicinal properties such as antioxidants and anticancer properties, antiaging and neurodegenerative diseases protective properties [23].

#### **1.4 Problem Statement**

Cancer disease remains a major cause of mortality globally. The deaths associated with cancer are increasing yearly, as reported by the world health organisation (WHO) [24]. Although there are various methods of cancer treatment, chemotherapy remains the most utilised form of cancer treatment. This could be due to the availability of varieties of chemotherapeutic agents. However, reports have indicated that most of the chemotherapeutic agents are toxic and had caused various unwanted side-effects, such as vomiting and hair



loss. This is understandably due to non-selective target of cells by the anticancer agents. Thus, the use of these agents poses a threat to human health.

All cancer treatments require prior diagnosis, which are mostly done using molecular imaging techniques. Magnetic resonance imaging (MRI) is often employed for this purpose. However, MRI contrast agents are administered to patients prior to the imaging. The contrast agents have also been reported to be toxic even in their chelate forms and less toxic in nanocomposites form.

A possible solution to this problem is to deliver the therapeutic agents to the cancer cells, which in turn could protect the healthy cells and by extension will eliminate the side-effects. Although some researchers have tried to develop anticancer drug and therapeutic agent's delivery systems via nanocarriers, a universal multi delivery system is still lacking. A holistic delivery system where both the therapeutic and the contrast agents can be delivered to the cancer cells region will be more effective in the treatment of cancer. Therefore, this work is focused on developing a theranostic delivery system where the diagnostic and the therapeutic agents can be delivered using different nano delivery agents.

## **1.5 Hypothesis**

Theranostic nanocomposites will reduce the problem of toxicities of therapeutic and contrast agents towards healthy cells and will provide better cancer diagnosis and treatment than the current toxic chemotherapy treatment and diagnosis with contrast agents. Better yet, it will provide the option of holistic and more precise approach towards treatment of cancer.

## **1.6 Scope of Study**

The inspiration of this study is derived from the fact that anticancer agents currently used in chemotherapy are toxic and harmful to normal human cells. The MRI contrast agents used in cancer diagnosis are equally toxic to certain extent. This project is aimed at producing unique nanocomposites that will simultaneously deliver both the therapeutic and diagnostic agents to the cancer sites. The theranostic nanocomposites in this work were developed using different nanocarriers, therapeutic agents, and contrast agents. The nanocomposites were tested with cancer and normal cell lines as well as with MR imaging equipment. The nanocomposites could serve as potential theranostic anticancer agents for more efficient and less toxic cancer treatment than the incumbent chemotherapy treatment.

## 1.7 Objectives

The purpose of this study is to develop theranostic delivery systems for simultaneous delivery of anticancer and MRI contrast agents. The systems will integrate various natural occurring phenolic therapeutic agents [gallic acid (GA), protocatechuic acid (PA) and chlorogenic acid (CA)], and diagnostic agents [gadolinium (Gd) and gold nanoparticles (AuNPs)] loaded on Zn/Mg-Al layered double hydroxide (LDH) and Graphene oxide (GO) nanocarriers. The theranostic systems have the capability to enhance MRI contrast via the T1 signals as well as to deliver the therapeutic agents simultaneously. The general toxicities, if any, of the contrast and therapeutic agents is expected to be reduced in the nanocomposite form.

The specific objectives for the theranostic delivery systems development are highlighted below:

- i. To prepare and incorporate the various therapeutic and contrast agents into the nanocarriers.
- ii. To characterize the physico-chemical properties of the synthesized nanocomposites loaded with the various therapeutic agents using various characterization techniques.
- iii. To study the cytotoxicity and therapeutic agents release pattern of the therapeutic agents loaded nanocomposites.
- iv. To evaluate the anticancer activities of the theranostic nanocomposites. To determine the MRI contrast enhancement properties of the prepared theranostic nanocomposites.

## REFERENCES

- [1]. Edwards SA. The nanotech pioneers: where are they taking us?: John Wiley & Sons; 2008.
- [2]. Usman MS, El Zowalaty ME, Shameli K, Zainuddin N, Salama M, Ibrahim NA. Synthesis, characterization, and antimicrobial properties of copper nanoparticles. *International journal of nanomedicine*. 2013;8:4467.
- [3]. Usman MS, Ibrahim NA, Shameli K, Zainuddin N, Yunus WMZW. Copper nanoparticles mediated by chitosan: synthesis and characterization via chemical methods. *Molecules*. 2012;17(12):14928-36.
- [4]. Drexler KE, Peterson C, Pergamit G. *Unbounding the future*. William Morrow, New York. 1991:294.
- [5]. Rouse M. Nanomedicine Drug index. <http://www.rxlist.com> (Accessed on 15 Dec 2016).
- [6]. Ventola CL. Progress in nanomedicine: approved and investigational nanodrugs. *Pharmacy and Therapeutics*. 2017;42(12):742.
- [7]. Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST. Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. *Advanced drug delivery reviews*. 2017;108:25-38.
- [8]. Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. *Pharmaceutical research*. 2016;33(10):2373-87.
- [9]. Tran S, DeGiovanni P-J, Piel B, Rai P. Cancer nanomedicine: a review of recent success in drug delivery. *Clinical and translational medicine*. 2017;6(1):44.
- [10]. Kim D-H. Image-Guided Cancer Nanomedicine. *Journal of Imaging*. 2018;4(1):18.
- [11]. Borel T, Sabliov C. Nanodelivery of bioactive components for food applications: types of delivery systems, properties, and their effect on ADME profiles and toxicity of nanoparticles. *Annual review of food science and technology*. 2014;5:197-213.

- [12].Yoo D, Lee J-H, Shin T-H, Cheon J. Theranostic magnetic nanoparticles. *Accounts of chemical research*. 2011;44(10):863-74.
- [13].Lee D-E, Koo H, Sun I-C, Ryu JH, Kim K, Kwon IC. Multifunctional nanoparticles for multimodal imaging and theragnosis. *Chemical Society Reviews*. 2012;41(7):2656-72.
- [14].Liu Z, Liang X-J. Nano-carbons as theranostics. *Theranostics*. 2012;2(3):235.
- [15].Barahuie F, Hussein MZ, Fakurazi S, Zainal Z. Development of drug delivery systems based on layered hydroxides for nanomedicine. *International journal of molecular sciences*. 2014;15(5):7750-86.
- [16].Ghotbi MY, Hussein MZ. Gallate–Zn–Al-layered double hydroxide as an intercalated compound with new controlled release formulation of anticarcinogenic agent. *Journal of Physics and Chemistry of Solids*. 2010;71(11):1565-70.
- [17].Liu Wh, Hsu Cc, Yin Mc. In vitro anti-*Helicobacter pylori* activity of diallyl sulphides and protocatechuic acid. *Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives*. 2008;22(1):53-7.
- [18].Liu C-L, Wang J-M, Chu C-Y, Cheng M-T, Tseng T-H. In vivo protective effect of protocatechuic acid on tert-butyl hydroperoxide-induced rat hepatotoxicity. *Food and Chemical Toxicology*. 2002;40(5):635-41.
- [19].Anter J, Romero-Jiménez M, Fernández-Bedmar Z, Villatoro-Pulido M, Analla M, Alonso-Moraga A. Antigenotoxicity, cytotoxicity, and apoptosis induction by apigenin, bisabolol, and protocatechuic acid. *Journal of medicinal food*. 2011;14(3):276-83.
- [20].Stagos D, Kazantzoglou G, Theofanidou D, Kakalopoulou G, Magiatis P, Mitaku S. Activity of grape extracts from Greek varieties of *Vitis vinifera* against mutagenicity induced by bleomycin and hydrogen peroxide in *Salmonella typhimurium* strain TA102. *Mutation Research/Genetic Toxicology and Environmental Mutagenesis*. 2006;609(2):165-75.
- [21].Lin HS, Yue BD, Ho PC. Determination of pterostilbene in rat plasma by a simple HPLC-UV method and its application in pre-clinical pharmacokinetic study. *Biomedical Chromatography*. 2009;23(12):1308-15.

- [22]. Nakamura K, Ito Y, Kawano Y, Kurozumi K, Kobune M, Tsuda H. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. *Gene therapy*. 2004;11(14):1155.
- [23]. Lu Y, Dong G, Gu Y, Ito Y, Wei Y. Separation of chlorogenic acid and concentration of trace caffeic acid from natural products by pH-zone-refining countercurrent chromatography. *Journal of separation science*. 2013;36(13):2210-5.
- [24]. Cancer. <http://www.who.int/news-room/fact-sheets/detail/cancer>. (Accessed on 15 December 2018).
- [25]. Reddy LH. Drug delivery to tumours: recent strategies. *Journal of Pharmacy and Pharmacology*. 2005;57(10):1231-42.
- [26]. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. *Nature reviews Drug discovery*. 2005;4(2):145.
- [27]. Emerich DF, Thanos CG. Nanotechnology and medicine. *Expert Opinion on Biological Therapy*. 2003;3(4):655-63.
- [28]. Chen F, Hong H, Zhang Y, Valdovinos HF, Shi S, Kwon GS. In vivo tumor targeting and image-guided drug delivery with antibody-conjugated, radiolabeled mesoporous silica nanoparticles. *ACS nano*. 2013;7(10):9027-39.
- [29]. Huang X, Jain PK, El-Sayed IH, El-Sayed MA. Determination of the minimum temperature required for selective photothermal destruction of cancer cells with the use of immunotargeted gold nanoparticles. *Photochemistry and photobiology*. 2006;82(2):412-7.
- [30]. Mieszawska AJ, Mulder WJ, Fayad ZA, Cormode DP. Multifunctional gold nanoparticles for diagnosis and therapy of disease. *Molecular pharmaceutics*. 2013;10(3):831-47.
- [31]. Santra S, Kaittanis C, Santiesteban OJ, Perez JM. Cell-specific, activatable, and theranostic prodrug for dual-targeted cancer imaging and therapy. *Journal of the American Chemical Society*. 2011;133(41):16680-8.
- [32]. Wang F, Liu B, Ip ACF, Liu J. Orthogonal Adsorption Onto Nano-Graphene Oxide Using Different Intermolecular Forces for Multiplexed Delivery. *Advanced Materials*. 2013;25(30):4087-92.

- [33]. Bullo S, Hussein MZ. Inorganic nanolayers: structure, preparation, and biomedical applications. *International journal of nanomedicine*. 2015;10:5609.
- [34]. Sun Y, Zhou J, Cai W, Zhao R, Yuan J. Hierarchically porous NiAl-LDH nanoparticles as highly efficient adsorbent for p-nitrophenol from water. *Applied Surface Science*. 2015;349:897-903.
- [35]. Ahmed AAA, Talib ZA, Hussein MZ, Flaifel MH, Al-Hada NM. Influence of Zn/Fe molar ratio on optical and magnetic properties of ZnO and ZnFe<sub>2</sub>O<sub>4</sub> nanocrystal as calcined products of layered double hydroxides. *Journal of Spectroscopy*. 2014;2014.
- [36]. Barahuie F, Hussein MZ, Arulselvan P, Fakurazi S, Zainal Z. Development of the anticancer potential of a chlorogenate-zinc layered hydroxide nanohybrid with controlled release property against various cancer cells. *Science of Advanced Materials*. 2013;5(12):1983-93.
- [37]. Chakraborty J, Roychowdhury S, Sengupta S, Ghosh S. Mg–Al layered double hydroxide–methotrexate nanohybrid drug delivery system: evaluation of efficacy. *Materials Science and Engineering: C*. 2013;33(4):2168-74.
- [38]. Chung C, Kim Y-K, Shin D, Ryoo S-R, Hong BH, Min D-H. Biomedical applications of graphene and graphene oxide. *Accounts of chemical research*. 2013;46(10):2211-24.
- [39]. Shen AJ, Li DL, Cai XJ, Dong CY, Dong HQ, Wen HY. Multifunctional nanocomposite based on graphene oxide for in vitro hepatocarcinoma diagnosis and treatment. *Journal of Biomedical Materials Research Part A*. 2012;100(9):2499-506.
- [40]. Zhang H, Wu H, Wang J, Yang Y, Wu D, Zhang Y. Graphene oxide-BaGdF<sub>5</sub> nanocomposites for multi-modal imaging and photothermal therapy. *Biomaterials*. 2015;42:66-77.
- [41]. Choi S-J, Oh J-M, Choy J-H. Biocompatible Nanoparticles Intercalated with Anticancer Drug for Target Delivery: Pharmacokinetic and Biodistribution Study. *Journal of Nanoscience and Nanotechnology*. 2010;10(4):2913-6.
- [42]. Oh J-M, Choi S-J, Lee G-E, Han S-H, Choy J-H. Inorganic Drug-Delivery Nanovehicle Conjugated with Cancer-Cell-Specific Ligand. *Advanced Functional Materials*. 2009;19(10):1617-24.

- [43].Oh J-M, Choi S-J, Kim S-T, Choy J-H. Cellular Uptake Mechanism of an Inorganic Nanovehicle and Its Drug Conjugates: Enhanced Efficacy Due To Clathrin-Mediated Endocytosis. *Bioconjugate Chemistry*. 2006;17(6):1411-7.
- [44].Barahuie F, Hussein MZ, Arulselvan P, Fakurazi S, Zainal Z. Drug delivery system for an anticancer agent, chlorogenate-Zn/Al-layered double hydroxide nanohybrid synthesised using direct co-precipitation and ion exchange methods. *Journal of Solid State Chemistry*. 2014;217:31-41.
- [45].Kura AU, Hussein MZ, Fakurazi S, Arulselvan P. Layered double hydroxide nanocomposite for drug delivery systems; bio-distribution, toxicity and drug activity enhancement. *Chemistry Central Journal*. 2014;8(1):47.
- [46].Sun X, Liu Z, Welsher K, Robinson JT, Goodwin A, Zaric S. Nanographene oxide for cellular imaging and drug delivery. *Nano Research*. 2008;1(3):203-12.
- [47].Lodish H BA, Zipursky SL, Matsudaira P, Baltimore D, Darnell J. *Molecular cell biology*. New York: WH Freeman. 1995.
- [48].Manus LM, Mastarone DJ, Waters EA, Zhang X-Q, Schultz-Sikma EA, MacRenaris KW. Gd(III)-Nanodiamond Conjugates for MRI Contrast Enhancement. *Nano Letters*. 2010;10(2):484-9.
- [49].Yang X, Zhang X, Liu Z, Ma Y, Huang Y, Chen Y. High-Efficiency Loading and Controlled Release of Doxorubicin Hydrochloride on Graphene Oxide. *The Journal of Physical Chemistry C*. 2008;112(45):17554-8.
- [50].Rana VK, Choi M-C, Kong J-Y, Kim GY, Kim MJ, Kim S-H. Synthesis and Drug-Delivery Behavior of Chitosan-Functionalized Graphene Oxide Hybrid Nanosheets. *Macromolecular Materials and Engineering*. 2011;296(2):131-40.
- [51].Hakimi M, Alimard P. Graphene: synthesis and applications in biotechnology-a review. 2012.
- [52].Marcano DC, Kosynkin DV, Berlin JM, Sinitskii A, Sun Z, Slesarev A. Improved synthesis of graphene oxide. *ACS nano*. 2010;4(8):4806-14.
- [53].Tang J, Sheng Y, Hu H, Shen Y. Macromolecular MRI contrast agents: structures, properties and applications. *Progress in Polymer Science*. 2013;38(3-4):462-502.

- [54].Lam T, Pouliot P, Avti PK, Lesage F, Kakkar AK. Superparamagnetic iron oxide based nanopores for imaging and theranostics. *Advances in colloid and interface science*. 2013;199:95-113.
- [55].Campbell JL, Arora J, Cowell SF, Garg A, Eu P, Bhargava SK. Quasi-cubic magnetite/silica core-shell nanoparticles as enhanced MRI contrast agents for cancer imaging. *PLoS One*. 2011;6(7):e21857.
- [56].Estelrich J, Sánchez-Martín MJ, Busquets MA. Nanoparticles in magnetic resonance imaging: from simple to dual contrast agents. *International journal of nanomedicine*. 2015;10:1727.
- [57].Aime S, Caravan P. Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. *Journal of Magnetic Resonance Imaging: An Official Journal of the International Society for Magnetic Resonance in Medicine*. 2009;30(6):1259-67.
- [58].FDA. Information on Gadolinium-Based Contrast Agents. <https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm142882.htm> (Accessed on 15 December 2017).
- [59].Ahmed N, Fessi H, Elaissari A. Theranostic applications of nanoparticles in cancer. *Drug discovery today*. 2012;17(17-18):928-34.
- [60].Xie J, Lee S, Chen X. Nanoparticle-based theranostic agents. *Advanced drug delivery reviews*. 2010;62(11):1064-79.
- [61].Liu TW, Chen J, Burgess L, Cao W, Shi J, Wilson BC. Multimodal bacteriochlorophyll theranostic agent. *Theranostics*. 2011;1:354.
- [62].Zhang Le, Zeng L, Pan Y, Luo S, Ren W, Gong A. Inorganic photosensitizer coupled Gd-based upconversion luminescent nanocomposites for in vivo magnetic resonance imaging and near-infrared-responsive photodynamic therapy in cancers. *Biomaterials*. 2015;44:82-90.
- [63].Fortin M-A, Petoral Jr RM, Söderlind F, Klasson A, Engström M, Veres T. Polyethylene glycol-covered ultra-small Gd<sub>2</sub>O<sub>3</sub> nanoparticles for positive contrast at 1.5 T magnetic resonance clinical scanning. *Nanotechnology*. 2007;18(39):395501.
- [64].Hartman KB, Laus S, Bolskar RD, Muthupillai R, Helm L, Toth E. Gadonanotubes as ultrasensitive pH-smart probes for magnetic resonance imaging. *Nano Letters*. 2008;8(2):415-9.



- [65].Liepold LO, Abedin MJ, Buckhouse ED, Frank JA, Young MJ, Douglas T. Supramolecular protein cage composite MR contrast agents with extremely efficient relaxivity properties. *Nano Letters*. 2009;9(12):4520-6.
- [66].Le Duc G, Roux S, Paruta-Tuarez A, Dufort S, Brauer E, Marais A. Advantages of gadolinium based ultrasmall nanoparticles vs molecular gadolinium chelates for radiotherapy guided by MRI for glioma treatment. *Cancer nanotechnology*. 2014;5(1):4.
- [67].Tian X, Shao Y, He H, Liu H, Shen Y, Huang W. Nanoamplifiers synthesized from gadolinium and gold nanocomposites for magnetic resonance imaging. *Nanoscale*. 2013;5(8):3322-9.
- [68].Hedlund A, Ahrén M, Gustafsson H, Abrikossova N, Warntjes M, Jönsson J-I. Gd<sub>2</sub>O<sub>3</sub> nanoparticles in hematopoietic cells for MRI contrast enhancement. *International journal of nanomedicine*. 2011;6:3233.
- [69].Zhang L, Liu T, Xiao Y, Yu D, Zhang N. Hyaluronic acid-chitosan nanoparticles to deliver Gd-DTPA for MR cancer imaging. *Nanomaterials*. 2015;5(3):1379-96.
- [70].Le W, Cui S, Chen X, Zhu H, Chen B, Cui Z. Facile synthesis of gd-functionalized gold nanoclusters as potential mri/ct contrast agents. *Nanomaterials*. 2016;6(4):65.
- [71].Wang L, Xing H, Zhang S, Ren Q, Pan L, Zhang K. A Gd-doped Mg-Al-LDH/Au nanocomposite for CT/MR bimodal imagings and simultaneous drug delivery. *Biomaterials*. 2013;34(13):3390-401.
- [72].Yang H-W, Huang C-Y, Lin C-W, Liu H-L, Huang C-W, Liao S-S. Gadolinium-functionalized nanographene oxide for combined drug and microRNA delivery and magnetic resonance imaging. *Biomaterials*. 2014;35(24):6534-42.
- [73].Zhang M, Cao Y, Chong Y, Ma Y, Zhang H, Deng Z. Graphene oxide based theranostic platform for T<sub>1</sub>-weighted magnetic resonance imaging and drug delivery. *ACS applied materials & interfaces*. 2013;5(24):13325-32.
- [74].Yoo SS, Guo L, Sun X, Shaw AR, Yuan Z, Löbenberg R. Fabrication and in vitro characterization of gadolinium-based nanoclusters for simultaneous drug delivery and radiation enhancement. *Nanotechnology*. 2016;27(38):385104.

- [75].Jin M, Yu D-G, Gerald CF, Williams GR, Bligh SA. Theranostic fibers for simultaneous imaging and drug delivery. *Molecular pharmaceutics*. 2016;13(7):2457-65.
- [76].Kam NWS, Liu Z, Dai H. Carbon nanotubes as intracellular transporters for proteins and DNA: an investigation of the uptake mechanism and pathway. *Angewandte Chemie*. 2006;118(4):591-5.
- [77].Berry CC. Possible exploitation of magnetic nanoparticle–cell interaction for biomedical applications. *Journal of Materials Chemistry*. 2005;15(5):543-7.
- [78].Bi X, Zhang H, Dou L. Layered double hydroxide-based nanocarriers for drug delivery. *Pharmaceutics*. 2014;6(2):298-332.
- [79].Caravan P. Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. *Chemical Society Reviews*. 2006;35(6):512-23.
- [80].Webb JA, Thomsen HS, Morcos SK, Radiology MoCMSCoESoU. The use of iodinated and gadolinium contrast media during pregnancy and lactation. *European radiology*. 2005;15(6):1234-40.
- [81].Bullo S, Hussein MZ, Hussein-Al-Ali SH, Arulselvan P, Fakurazi S. Antituberculosis nanodelivery system with controlled-release properties based on para-amino salicylate–zinc aluminum-layered double-hydroxide nanocomposites. *Drug design, development and therapy*. 2013;7:1365.
- [82].Yang K, Zhang S, Zhang G, Sun X, Lee S-T, Liu Z. Graphene in mice: ultrahigh in vivo tumor uptake and efficient photothermal therapy. *Nano Letters*. 2010;10(9):3318-23.
- [83].Zhang L, Xia J, Zhao Q, Liu L, Zhang Z. Functional graphene oxide as a nanocarrier for controlled loading and targeted delivery of mixed anticancer drugs. *small*. 2010;6(4):537-44.
- [84].Fiorillo M, Verre AF, Iliut M, Peiris-Pagés M, Ozsvári B, Gandara R. Graphene oxide selectively targets cancer stem cells, across multiple tumor types: implications for non-toxic cancer treatment, via “differentiation-based nano-therapy”. *Oncotarget*. 2015;6(6):3553.
- [85].Liu J, Fu S, Yuan B, Li Y, Deng Z. Toward a universal “adhesive nanosheet” for the assembly of multiple nanoparticles based on a protein-induced reduction/decoration of graphene oxide. *Journal of the American Chemical Society*. 2010;132(21):7279-81.

- [86].Liu Z, Robinson JT, Sun X, Dai H. PEGylated nanographene oxide for delivery of water-insoluble cancer drugs. *Journal of the American Chemical Society*. 2008;130(33):10876-7.
- [87].Sun G, Zhou L, Liu Y, Zhao Z. Biocompatible Gd III-functionalized fluorescent gold nanoclusters for optical and magnetic resonance imaging. *New Journal of Chemistry*. 2013;37(4):1028-35.
- [88].Barahuie F, Hussein MZ, Gani SA, Fakurazi S, Zainal Z. Synthesis of protocatechuic acid–zinc/aluminium–layered double hydroxide nanocomposite as an anticancer nanodelivery system. *Journal of Solid State Chemistry*. 2015;221:21-31.
- [89].Barahuie F, Hussein MZ, Hussein-Al-Ali SH, Arulselvan P, Fakurazi S, Zainal Z. Preparation and controlled-release studies of a protocatechuic acid-magnesium/aluminum-layered double hydroxide nanocomposite. *International journal of nanomedicine*. 2013;8:1975.
- [90].Barahuie F, Bullo S, Dorniani D, Fakurazi S, Karthivashan G, Hussein MZ. Graphene oxide as a nanocarrier for controlled release and targeted delivery of an anticancer active agent, chlorogenic acid. *Materials Science and Engineering: C*. 2017;74:177-85.
- [91].Dorniani D, Bullo S, Barahuie F, Arulselvan P, Hussein MZB, Fakurazi S. Graphene oxide-gallic acid nanodelivery system for cancer therapy. *Nanoscale research letters*. 2016;11(1):491.
- [92].Bullo S, Hussein MZ, Hussein-Al-Ali SH, Arulselvan P, Fakurazi S. Sustained release formulation of an anti-tuberculosis drug based on para-amino salicylic acid-zinc layered hydroxide nanocomposite. *Chemistry Central Journal*. 2013;7(1):72.
- [93].Barahuie F, Hussein MZ, Gani SA, Fakurazi S, Zainal Z. Anticancer nanodelivery system with controlled release property based on protocatechuate–zinc layered hydroxide nanohybrid. *International journal of nanomedicine*. 2014;9:3137.
- [94].Tan JM, Karthivashan G, Gani SA, Fakurazi S, Hussein MZ. Biocompatible polymers coated on carboxylated nanotubes functionalized with betulinic acid for effective drug delivery. *Journal of Materials Science: Materials in Medicine*. 2016;27(2):26.
- [95].Kura AU, Hussein-Al-Ali SH, Hussein MZ, Fakurazi S. Preparation of Tween 80-Zn/Al-levodopa-layered double hydroxides nanocomposite for drug delivery system. *The Scientific World Journal*. 2014;2014.

- [96].Tan JM, Karthivashan G, Arulselvan P, Fakurazi S, Hussein MZ. Characterization and in vitro studies of the anticancer effect of oxidized carbon nanotubes functionalized with betulinic acid. *Drug design, development and therapy*. 2014;8:2333.
- [97].Nasir S, Hussein MZ, Yusof NA, Zainal Z. Oil palm waste-based precursors as a renewable and economical carbon sources for the preparation of reduced graphene oxide from graphene oxide. *Nanomaterials*. 2017;7(7):182.
- [98].Singh M, Singh S, Prasad S, Gambhir I. Nanotechnology in medicine and antibacterial effect of silver nanoparticles. *Digest Journal of Nanomaterials and Biostructures*. 2008;3(3):115-22.
- [99].Kovanda F, Jindova E, Dousova B, Kolousek D, Plestil J, Sedlakova Z. Layered double hydroxides intercalated with organic anions and their application in preparation of ldh/polymer nanocomposites. *Acta geodynamica et geomaterialia*. 2009;6(153):111-9.
- [100].Swierczewska M, Liu G, Lee S, Chen X. High-sensitivity nanosensors for biomarker detection. *Chemical Society Reviews*. 2012;41(7):2641-55.
- [101].Xu W, Kattel K, Park JY, Chang Y, Kim TJ, Lee GH. Paramagnetic nanoparticle T 1 and T 2 MRI contrast agents. *Physical Chemistry Chemical Physics*. 2012;14(37):12687-700.
- [102].Jeong Kim T, Seok Chae K, Chang Y, Ho Lee G. Gadolinium oxide nanoparticles as potential multimodal imaging and therapeutic agents. *Current topics in medicinal chemistry*. 2013;13(4):422-33.
- [103].Thrall JH. Nanotechnology and medicine. *Radiology*. 2004;230(2):315-8.
- [104].Usman MS, Hussein MZ, Fakurazi S, Saad FFA. Gadolinium-based layered double hydroxide and graphene oxide nano-carriers for magnetic resonance imaging and drug delivery. *Chemistry Central Journal*. 2017;11(1):47.
- [105].Cherry SR, editor. *Multimodality imaging: Beyond pet/ct and spect/ct. Seminars in nuclear medicine*; 2009: Elsevier.
- [106].Srinivasan M, Rajabi M, Mousa SA. Multifunctional nanomaterials and their applications in drug delivery and cancer therapy. *Nanomaterials*. 2015;5(4):1690-703.

- [107]. Elgqvist J. Nanoparticles as theranostic vehicles in experimental and clinical applications—focus on prostate and breast cancer. *International journal of molecular sciences*. 2017;18(5):1102.
- [108]. Kim KS, Park W, Hu J, Bae YH, Na K. A cancer-recognizable MRI contrast agents using pH-responsive polymeric micelle. *Biomaterials*. 2014;35(1):337-43.
- [109]. Gwak G-H, Kim M-K, Oh J-M. Composites of quasi-colloidal layered double hydroxide nanoparticles and agarose hydrogels for chromate removal. *Nanomaterials*. 2016;6(2):25.
- [110]. Zhang Y, Liu X, Zhang C, He M, Lu X. Interlayer Structures and Dynamics of Arsenate and Arsenite Intercalated Layered Double Hydroxides: A First Principles Study. *Minerals*. 2017;7(4):53.
- [111]. Dorniani D, Hussein MZ, Kura AU, Fakurazi S, Shaari AH, Ahmad Z. Preparation of Fe<sub>3</sub>O<sub>4</sub> magnetic nanoparticles coated with gallic acid for drug delivery. *International journal of nanomedicine*. 2012;7:5745.
- [112]. Choi S-J, Choi GE, Oh J-M, Oh Y-J, Park M-C, Choy J-H. Anticancer drug encapsulated in inorganic lattice can overcome drug resistance. *Journal of Materials Chemistry*. 2010;20(42):9463-9.
- [113]. Long NN, Kiem CD, Doanh SC, Nguyet CT, Hang PT, Thien ND., editors. Synthesis and optical properties of colloidal gold nanoparticles. *Journal of Physics: Conference Series*; 2009: IOP Publishing.
- [114]. Hussein MZ, Zainal Z, Yahaya AH, Foo DWV. Controlled release of a plant growth regulator,  $\alpha$ -naphthaleneacetate from the lamella of Zn–Al-layered double hydroxide nanocomposite. *Journal of Controlled Release*. 2002;82(2-3):417-27.
- [115]. Oh J-M, Choi S-J, Kim S-T, Choy J-H. Cellular uptake mechanism of an inorganic nanovehicle and its drug conjugates: enhanced efficacy due to clathrin-mediated endocytosis. *Bioconjugate Chemistry*. 2006;17(6):1411-7.
- [116]. Dorniani D, Kura AU, Hussein-AI-Ali SH, Hussein B, Zobir M, Fakurazi S. In vitro sustained release study of gallic acid coated with magnetite-PEG and magnetite-PVA for drug delivery system. *The Scientific World Journal*. 2014;2014.

- [117].Kong X, Jin L, Wei M, Duan X. Antioxidant drugs intercalated into layered double hydroxide: Structure and in vitro release. *Applied Clay Science*. 2010;49(3):324-9.
- [118].Zhang Z, Liu W, Zheng Y, Jin L, Yao W, Gao X. SGP-2, an acidic polysaccharide from *Sarcandra glabra*, inhibits proliferation and migration of human osteosarcoma cells. *Food & function*. 2014;5(1):167-75.
- [119].Chieng BW, Ibrahim NA, Yunus WMZW, Hussein MZ. Poly (lactic acid)/poly (ethylene glycol) polymer nanocomposites: effects of graphene nanoplatelets. *Polymers*. 2013;6(1):93-104.
- [120]. Mukherjee P, Bhattacharya R, Bone N, Lee YK, Patra CR, Wang S. Potential therapeutic application of gold nanoparticles in B-chronic lymphocytic leukemia (BCLL): enhancing apoptosis. *Journal of nanobiotechnology*. 2007;5(1):4.
- [121].Zarabi MF, Arshadi N, Farhangi A, Akbarzadeh A. Preparation and Characterization of Gold Nanoparticles with Amino Acids, Examination of Their Stability. *Indian Journal of Clinical Biochemistry*. 2014;29(3):306-14.
- [122].King SR, Shimmon S, Gentle AR, Westerhausen MT, Dowd A, McDonagh AM. Remarkable thermal stability of gold nanoparticles functionalised with ruthenium phthalocyanine complexes. *Nanotechnology*. 2016;27(21):215702.
- [123].Patra JK, Baek K-H. Novel green synthesis of gold nanoparticles using *Citrullus lanatus* rind and investigation of proteasome inhibitory activity, antibacterial, and antioxidant potential. *International journal of nanomedicine*. 2015;10:7253.
- [124].Zawada K, Tomaszewski W, Megiel E. A smart synthesis of gold/polystyrene core-shell nanohybrids using TEMPO coated nanoparticles. *RSC Advances*. 2014;4(45):23876-85.
- [125].Sugano K, Kansy M, Artursson P, Avdeef A, Bendels S, Di L. Coexistence of passive and carrier-mediated processes in drug transport. *Nature reviews Drug discovery*. 2010;9(8):597.
- [126]. Xu ZP, Lu GM. Layered double hydroxide nanomaterials as potential cellular drug delivery agents. *Pure and applied chemistry*. 2006;78(9):1771-9.

- [127].Thomsen HS. Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Springer; 2006.
- [128].Sparreboom A, Baker SD, Verweij J. Paclitaxel repackaged in an albumin-stabilized nanoparticle: handy or just a dandy? : American Society of Clinical Oncology; 2005.
- [129].Tyner KM, Schiffman SR, Giannelis EP. Nanobiohybrids as delivery vehicles for camptothecin. *Journal of Controlled Release*. 2004;95(3):501-14.
- [130].Ehrlich P. Chemotherapy. The collected papers of Paul Ehrlich: Elsevier; 1960. p. 505-18.
- [131].Nie S. Understanding and overcoming major barriers in cancer nanomedicine. *Nanomedicine*. 2010;5(4):523-8.
- [132].Atabaev TS, Lee JH, Shin YC, Han D-W, Choo KS, Jeon UB. Eu, Gd-codoped yttria nanoprobe for optical and T1-weighted magnetic resonance imaging. *Nanomaterials*. 2017;7(2):35.
- [133].Chow EK-H, Ho D. Cancer nanomedicine: from drug delivery to imaging. *Science translational medicine*. 2013;5(216):216rv4-rv4.
- [134].Dong L, Yan L, Hou W-G, Liu S-J. Synthesis and release behavior of composites of camptothecin and layered double hydroxide. *Journal of Solid State Chemistry*. 2010;183(8):1811-6.
- [135].Hassoun M, Schie IW, Tolstik T, Stanca SE, Krafft C, Popp J. Surface-enhanced Raman spectroscopy of cell lysates mixed with silver nanoparticles for tumor classification. *Beilstein journal of nanotechnology*. 2017;8:1183.
- [136].Jagminas A, Mikalauskaitė A, Karabanovas V, Vaičiūnienė J. Methionine-mediated synthesis of magnetic nanoparticles and functionalization with gold quantum dots for theranostic applications. *Beilstein journal of nanotechnology*. 2017;8:1734.
- [137].Straßer M, Schrauth JH, Dembski S, Haddad D, Ahrens B, Schweizer S. Calcium fluoride based multifunctional nanoparticles for multimodal imaging. *Beilstein journal of nanotechnology*. 2017;8:1484-93.
- [138].Varan C, Bilensoy E. Cationic PEGylated polycaprolactone nanoparticles carrying post-operation docetaxel for glioma treatment. *Beilstein journal of nanotechnology*. 2017;8:1446-56.

- [139].Varan G, Benito JM, Mellet CO, Bilensoy E. Development of polycationic amphiphilic cyclodextrin nanoparticles for anticancer drug delivery. *Beilstein journal of nanotechnology*. 2017;8:1457-68.
- [140].López-Dávila V, Seifalian AM, Loizidou M. Organic nanocarriers for cancer drug delivery. *Current opinion in pharmacology*. 2012;12(4):414-9.
- [141].Choi G, Piao H, Alothman ZA, Vinu A, Yun C-O, Choy J-H. Anionic clay as the drug delivery vehicle: tumor targeting function of layered double hydroxide-methotrexate nanohybrid in C33A orthotopic cervical cancer model. *International journal of nanomedicine*. 2016;11:337.
- [142].Bellin MF. Gadolinium-Based Contrast Agents. In H. S. Thomsen & J A W Webb (Eds). 2009; *Contrast Media: Safety Issues and ESUR Guidelines* Berlin, Heidelberg: Springer Berlin Heidelberg:199-204.
- [143].Kim H-J, Ryu K, Kang J-H, Choi A-J, Kim T-i, Oh J-M. Anticancer activity of ferulic acid-inorganic nanohybrids synthesized via two different hybridization routes, reconstruction and exfoliation-reassembly. *The Scientific World Journal*. 2013;2013.
- [144].Benyettou F, Lalatonne Y, Chebbi I, Di Benedetto M, Serfaty J-M, Lecouvey M. A multimodal magnetic resonance imaging nanoplatfom for cancer theranostics. *Physical Chemistry Chemical Physics*. 2011;13(21):10020-7.
- [145].Chen Y-W, Liou G-G, Pan H-B, Tseng H-H, Hung Y-T, Chou C-P. Specific detection of CD133-positive tumor cells with iron oxide nanoparticles labeling using noninvasive molecular magnetic resonance imaging. *International journal of nanomedicine*. 2015;10:6997.
- [146].Huang C-H, Tsourkas A. Gd-based macromolecules and nanoparticles as magnetic resonance contrast agents for molecular imaging. *Current topics in medicinal chemistry*. 2013;13(4):411-21.
- [147].Belay A, Gholap A. Characterization and determination of chlorogenic acids (CGA) in coffee beans by UV-Vis spectroscopy. *African Journal of Pure and Applied Chemistry*. 2009;3(11):34-240.
- [148].Arranja AG, Pathak V, Lammers T, Shi Y. Tumor-targeted nanomedicines for cancer theranostics. *Pharmacological research*. 2017;115:87-95.



- [149].Usman MS, Hussein MZ, Fakurazi S, Masarudin MJ, Ahmad Saad FF. Gadolinium-doped gallic acid-zinc/aluminium-layered double hydroxide/gold theranostic nanoparticles for a bimodal magnetic resonance imaging and drug delivery system. *Nanomaterials*. 2017;7(9):244.
- [150].Zuo H, Chen W, Li B, Xu K, Cooper H, Gu Z. MnAl Layered Double Hydroxide Nanoparticles as a Dual-Functional Platform for Magnetic Resonance Imaging and siRNA Delivery. *Chemistry–A European Journal*. 2017;23(57):14299-306.
- [151].Ajat M, Mohd M, Yusoff K, Hussein MZ. Synthesis of glutamate-zinc-aluminium-layered double hydroxide nanobiocomposites and cell viability study. *Current Nanoscience*. 2008;4(4):391-6.
- [152].Wei Y, Gao Y, Xie Q, Zhang G, Fu W. Isolation of chlorogenic acid from *Flaveria bidentis* (L.) Kuntze by CCC and synthesis of chlorogenic acid-intercalated layered double hydroxide. *Chromatographia*. 2011;73(1):97-102.
- [153].Raffi M, Mehrwan S, Bhatti TM, Akhter JI, Hameed A, Yawar W. Investigations into the antibacterial behavior of copper nanoparticles against *Escherichia coli*. *Annals of microbiology*. 2010;60(1):75-80.
- [154].Cao G. *Nanostructures & nanomaterials: synthesis, properties & applications*: Imperial college press; 2004.
- [155].Ng KK, Lovell JF, Zheng G. Lipoprotein-inspired nanoparticles for cancer theranostics. *Accounts of chemical research*. 2011;44(10):1105-13.
- [156].Krishnamoorthy K, Navaneethaiyer U, Mohan R, Lee J, Kim S-J. Graphene oxide nanostructures modified multifunctional cotton fabrics. *Applied Nanoscience*. 2012;2(2):119-26.
- [157].Mirza AZ, Siddiqui FA. Nanomedicine and drug delivery: a mini review. *International Nano Letters*. 2014;4(1):94.
- [158].Boverhof DR, Bramante CM, Butala JH, Clancy SF, Lafranconi M, West J. Comparative assessment of nanomaterial definitions and safety evaluation considerations. *Regulatory toxicology and pharmacology*. 2015;73(1):137-50.
- [159].Menezes J, Da Silva T, Dos Santos J, Catari E, Meneghetti M, Da Matta C. Layered double hydroxides (LDHs) as carrier of antimony

aimed for improving leishmaniasis chemotherapy. *Applied Clay Science*. 2014;91:127-34.

- [160].Yuan J, Zhou X, Cao W, Bi L, Zhang Y, Yang Q. Improved antitumor efficacy and pharmacokinetics of bufalin via PEGylated liposomes. *Nanoscale research letters*. 2017;12(1):585.
- [161].Sheng Z, Hu D, Xue M, He M, Gong P, Cai L. Indocyanine green nanoparticles for theranostic applications. *Nano-Micro Letters*. 2013;5(3):145-50.
- [162].Yin M-C, Lin C-C, Wu H-C, Tsao S-M, Hsu C-K. Apoptotic effects of protocatechuic acid in human breast, lung, liver, cervix, and prostate cancer cells: potential mechanisms of action. *Journal of agricultural and food chemistry*. 2009;57(14):6468-73.
- [163].Nakamura Y, Torikai K, Ohto Y, Murakami A, Tanaka T, Ohigashi H. A simple phenolic antioxidant protocatechuic acid enhances tumor promotion and oxidative stress in female ICR mouse skin: dose-and timing-dependent enhancement and involvement of bioactivation by tyrosinase. *Carcinogenesis*. 2000;21(10):1899-907.
- [164]. Cavani F, Trifiro F, Vaccari A. Hydrotalcite-type anionic clays: Preparation, properties and applications. *Catalysis today*. 1991;11(2):173-301.
- [165].Uppal MA, Kafizas A, Ewing MB, Parkin IP. The room temperature formation of gold nanoparticles from the reaction of cyclohexanone and auric acid; a transition from dendritic particles to compact shapes and nanoplates. *Journal of Materials Chemistry A*. 2013;1(25):7351-9.
- [166].Dorniani D, Kura AU, Hussein MZB, Fakurazi S, Shaari AH, Ahmad Z. Controlled-release formulation of perindopril erbumine loaded PEG-coated magnetite nanoparticles for biomedical applications. *Journal of materials science*. 2014;49(24):8487-97.
- [167].Eisenberg D, Kauzmann W. *The structure and properties of water* Oxford Univ. Press, New York. 1969.
- [168].Aisawa S, Sasaki S, Takahashi S, Hirahara H, Nakayama H, Narita E. Intercalation of amino acids and oligopeptides into Zn–Al layered double hydroxide by coprecipitation reaction. *Journal of Physics and Chemistry of Solids*. 2006;67(5-6):920-5.
- [169].Hancock Y. The 2010 Nobel Prize in physics—Ground-breaking experiments on graphene. *Journal of Physics D: Applied Physics*. 2011;44(47):473001.

- [170].Novoselov KS, Geim AK, Morozov SV, Jiang D, Zhang Y, Dubonos SV. Electric field effect in atomically thin carbon films. *science*. 2004;306(5696):666-9.
- [171].Zhu Y, Murali S, Cai W, Li X, Suk JW, Potts JR. Graphene and graphene oxide: synthesis, properties, and applications. *Advanced Materials*. 2010;22(35):3906-24.
- [172].Goenka S, Sant V, Sant S. Graphene-based nanomaterials for drug delivery and tissue engineering. *Journal of Controlled Release*. 2014;173:75-88.
- [173].Huang Y-S, Lu Y-J, Chen J-P. Magnetic graphene oxide as a carrier for targeted delivery of chemotherapy drugs in cancer therapy. *Journal of Magnetism and Magnetic Materials*. 2017;427:34-40.
- [174].Kim J, Cote LJ, Kim F, Yuan W, Shull KR, Huang J. Graphene oxide sheets at interfaces. *Journal of the American Chemical Society*. 2010;132(23):8180-6.
- [175].Carr D, Brown J, Bydder G, Steiner R, Weinmann H, Speck U. Gadolinium-DTPA as a contrast agent in MRI: initial clinical experience in 20 patients. *American Journal of Roentgenology*. 1984;143(2):215-24.
- [176].Balcioglu M, Rana M, Yigit MV. Doxorubicin loading on graphene oxide, iron oxide and gold nanoparticle hybrid. *Journal of Materials Chemistry B*. 2013;1(45):6187-93.
- [177].Chao C-Y, Yin M-C. Antibacterial effects of roselle calyx extracts and protocatechuic acid in ground beef and apple juice. *Foodborne Pathogens and Disease*. 2009;6(2):201-6.
- [178].Jaijoy K, Soonthornchareonnon N, Panthong A, Sireeratawong S. Anti-inflammatory and analgesic activities of the water extract from the fruit of *Phyllanthus emblica* Linn. *International Journal of Applied Research in Natural Products*. 2010;3(2):28-35.
- [179].Guan S, Bao Y-M, Jiang B, An L-J. Protective effect of protocatechuic acid from *Alpinia oxyphylla* on hydrogen peroxide-induced oxidative PC12 cell death. *European journal of pharmacology*. 2006;538(1-3):73-9.

- [180].Sahu A, Choi WI, Lee JH, Tae G. Graphene oxide mediated delivery of methylene blue for combined photodynamic and photothermal therapy. *Biomaterials*. 2013;34(26):6239-48.
- [181].Zhang B, Yang X, Wang Y, Zhai G. Heparin modified graphene oxide for pH-sensitive sustained release of doxorubicin hydrochloride. *Materials Science and Engineering: C*. 2017;75:198-206.
- [182].Guo Y, Sun X, Liu Y, Wang W, Qiu H, Gao J. One pot preparation of reduced graphene oxide (RGO) or Au (Ag) nanoparticle-RGO hybrids using chitosan as a reducing and stabilizing agent and their use in methanol electrooxidation. *Carbon*. 2012;50(7):2513-23.
- [183].Verma S, Mungse HP, Kumar N, Choudhary S, Jain SL, Sain B. Graphene oxide: an efficient and reusable carbocatalyst for aza-Michael addition of amines to activated alkenes. *Chemical Communications*. 2011;47(47):12673-5.
- [184].Kuila T, Bose S, Khanra P, Kim NH, Rhee KY, Lee JH. Characterization and properties of in situ emulsion polymerized poly (methyl methacrylate)/graphene nanocomposites. *Composites part A: applied science and manufacturing*. 2011;42(11):1856-61.
- [185].He H, Li Y, Jia X-R, Du J, Ying X, Lu W-L. PEGylated Poly (amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors. *Biomaterials*. 2011;32(2):478-87.
- [186].Huang J, Zong C, Shen H, Liu M, Chen B, Ren B. Mechanism of cellular uptake of graphene oxide studied by surface-enhanced raman spectroscopy. *small*. 2012;8(16):2577-84.
- [187].Manus LM, Mastarone DJ, Waters EA, Zhang X-Q, Schultz-Sikma EA, MacRenaris KW. Gd (III)-nanodiamond conjugates for MRI contrast enhancement. *Nano Letters*. 2009;10(2):484-9.
- [188].Pylypchuk IV, Kołodyńska D, Koziół M, Gorbyk P. Gd-DTPA adsorption on chitosan/magnetite nanocomposites. *Nanoscale research letters*. 2016;11(1):168.
- [189].Luo K, Tian J, Liu G, Sun J, Xia C, Tang H. Self-assembly of SiO<sub>2</sub>/Gd-DTPA-polyethylenimine nanocomposites as magnetic resonance imaging probes. *Journal of Nanoscience and Nanotechnology*. 2010;10(1):540-8.
- [190].Wang F, Peng E, Zheng B, Li SFY, Xue JM. Synthesis of Water-Dispersible Gd<sub>2</sub>O<sub>3</sub>/GO Nanocomposites with Enhanced MRI T<sub>1</sub>

Relaxivity. *The Journal of Physical Chemistry C*. 2015;119(41):23735-42.

- [191]. Xu ZP, Kurniawan ND, Bartlett PF, Lu GQ. Enhancement of relaxivity rates of Gd-DTPA complexes by intercalation into layered double hydroxide nanoparticles. *Chemistry–A European Journal*. 2007;13(10):2824-30.
- [192]. Muhulet A, Miculescu F, Voicu SI, Schütt F, Thakur VK, Mishra YK. Fundamentals and scopes of doped carbon nanotubes towards energy and biosensing applications. *Materials Today Energy*. 2018;9:154-86.
- [193]. Begum A, Tripathi KM, Sarkar S. Water-Induced Formation, Characterization, and Photoluminescence of Carbon Nanotube-Based Composites of Gadolinium (III) and Platinum (II) Dithiolenes. *Chemistry–A European Journal*. 2014;20(50):16657-61.
- [194]. Ovid'Ko I. Mechanical properties of graphene. *Rev Adv Mater Sci*. 2013;34(1):1-11.
- [195]. Shen H, Zhang L, Liu M, Zhang Z. Biomedical applications of graphene. *Theranostics*. 2012;2(3):283.
- [196]. Baradaran S, Moghaddam E, Basirun WJ, Mehrali M, Sookhajian M, Hamdi M. Mechanical properties and biomedical applications of a nanotube hydroxyapatite-reduced graphene oxide composite. *Carbon*. 2014;69:32-45.
- [197]. Dreyer DR, Jia HP, Bielawski CW. Graphene oxide: a convenient carbocatalyst for facilitating oxidation and hydration reactions. *Angewandte Chemie*. 2010;122(38):6965-8.
- [198]. Yang K, Feng L, Shi X, Liu Z. Nano-graphene in biomedicine: theranostic applications. *Chemical Society Reviews*. 2013;42(2):530-47.
- [199]. Gobbo OL, Sjaastad K, Radomski MW, Volkov Y, Prina-Mello A. Magnetic nanoparticles in cancer theranostics. *Theranostics*. 2015;5(11):1249.
- [200]. Josefsen LB, Boyle RW. Unique diagnostic and therapeutic roles of porphyrins and phthalocyanines in photodynamic therapy, imaging and theranostics. *Theranostics*. 2012;2(9):916.

- [201].Tang LA, Lee WC, Shi H, Wong EY, Sadovoy A, Gorelik S. Highly wrinkled cross-linked graphene oxide membranes for biological and charge-storage applications. *small*. 2012;8(3):423-31.
- [202].Tuinstra F, Koenig JL. Raman spectrum of graphite. *The Journal of Chemical Physics*. 1970;53(3):1126-30.
- [203]. Ferrari AC. Raman spectroscopy of graphene and graphite: disorder, electron–phonon coupling, doping and nonadiabatic effects. *Solid state communications*. 2007;143(1-2):47-57.
- [204].Akhavan O, Bijanzad K, Mirsepah A. Synthesis of graphene from natural and industrial carbonaceous wastes. *RSC Advances*. 2014;4(39):20441-8.
- [205].Wahab R, Dwivedi S, Khan F, Mishra YK, Hwang I, Shin H-S. Statistical analysis of gold nanoparticle-induced oxidative stress and apoptosis in myoblast (C2C12) cells. *Colloids and surfaces B: Biointerfaces*. 2014;123:664-72.